EFFECT OF PUERARIN ON THE PROLIFERATION AND DIFFERENTIATION OF OSTEOBLASTS AND THE EXPRESSION OF TYPE I COLLAGEN MRNA IN A HIGH-GLUCOSE ENVIRONMENT

Overview

Journal Acta Endocrinol (Buchar)

Specialty Endocrinology

Date 2020 Dec 28

PMID 33363648

Authors

X H Wang

X W Shi

X X Luo

D H Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effect of puerarin (Pue) on the proliferation and differentiation of osteoblasts and the expression of type I collagen(Coll I) mRNA in a high-glucose (HG) environment, and to provide evidence for the clinical treatment of diabetic osteoporosis(DOP).

Subjects And Methods: The proliferation of osteoblasts from three groups - the control group, the HS group, and the HG+Pue (10-10 M) group - was cultivated for 72 h and evaluated using the methyl thiazolyltetrazolium (MTT) assay.

Results: The MTT values and the ALP activities in all experimental groups were significantly lower than those in the control group, and the MTT values and the ALP activities in the HG+Pue group were significantly higher than those in the HS group. Coll I mRNA expression in all experimental groups was significantly lower than that in the control group, while that in the HG+Pue group was significantly higher than that in the HG group.

Conclusions: The proliferation and differentiation of osteoblasts and the expression of Coll I mRNA were inhibited by high glucose, but Pue can increase the proliferation and differentiation as well as the expression of Coll I mRNA in the osteoblasts, indicating that Pue could be therapeutically beneficial against DOP.

References

Liu X, Mei Z, Qian J, Zeng Y, Wang M . Puerarin partly counteracts the inflammatory response after cerebral ischemia/reperfusion via activating the cholinergic anti-inflammatory pathway. Neural Regen Res. 2014; 8(34):3203-15. PMC: 4146182. DOI: 10.3969/j.issn.1673-5374.2013.34.004. View

Jackuliak P, Payer J . Osteoporosis, fractures, and diabetes. Int J Endocrinol. 2014; 2014:820615. PMC: 4094869. DOI: 10.1155/2014/820615. View

Zou Z, Liu Z, Gong M, Han B, Wang S, Liang S . Intervention effects of puerarin on blood stasis in rats revealed by a (1)H NMR-based metabonomic approach. Phytomedicine. 2015; 22(3):333-43. DOI: 10.1016/j.phymed.2015.01.006. View

Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R . Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip. 2015; 28(6):1127-1137. PMC: 4434053. DOI: 10.1080/13102818.2014.967827. View

Saller A, Maggi S, Romanato G, Tonin P, Crepaldi G . Diabetes and osteoporosis. Aging Clin Exp Res. 2008; 20(4):280-9. DOI: 10.1007/BF03324857. View

Reginster J, Burlet N . Osteoporosis: a still increasing prevalence. Bone. 2006; 38(2 Suppl 1):S4-9. DOI: 10.1016/j.bone.2005.11.024. View

Xuan B, Zhou Y, Yang R, Li N, Min Z, Chiou G . Improvement of ocular blood flow and retinal functions with puerarin analogs. J Ocul Pharmacol Ther. 1999; 15(3):207-16. DOI: 10.1089/jop.1999.15.207. View

Wang Q, Ge X, Tian X, Zhang Y, Zhang J, Zhang P . Soy isoflavone: The multipurpose phytochemical (Review). Biomed Rep. 2014; 1(5):697-701. PMC: 3916987. DOI: 10.3892/br.2013.129. View

Pan H, Li G . Protecting mechanism of puerarin on the brain neurocyte of rat in acute local ischemia brain injury and local cerebral ischemia-reperfusion injury. Yakugaku Zasshi. 2008; 128(11):1689-98. DOI: 10.1248/yakushi.128.1689. View

10.

Wang N, Wang X, Cheng W, Cao H, Zhang P, Qin L . Puerarin promotes osteogenesis and inhibits adipogenesis in vitro. Chin Med. 2013; 8(1):17. PMC: 3765709. DOI: 10.1186/1749-8546-8-17. View

11.

Yuan S, Sheng T, Liu L, Zhang Y, Liu X, Ma T . Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro. Chin J Nat Med. 2016; 14(4):265-269. DOI: 10.1016/S1875-5364(16)30026-7. View

12.

Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider J . Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2014; 14:33. PMC: 4021186. DOI: 10.1186/1472-6823-14-33. View

13.

Cherdshewasart W, Sutjit W, Pulcharoen K, Chulasiri M . Mutagenic and antimutagenic effects of the traditional herb used for treating erectile dysfunction, Butea superba Roxb. Biosci Biotechnol Biochem. 2010; 74(5):923-7. DOI: 10.1271/bbb.90727. View

14.

Paschou S, Dede A, Anagnostis P, Vryonidou A, Morganstein D, Goulis D . Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017; 102(10):3621-3634. DOI: 10.1210/jc.2017-00042. View

15.

Lagari V, Levis S . Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom. 2013; 16(4):445-9. DOI: 10.1016/j.jocd.2013.08.011. View

16.

Sealand R, Razavi C, Adler R . Diabetes mellitus and osteoporosis. Curr Diab Rep. 2013; 13(3):411-8. DOI: 10.1007/s11892-013-0376-x. View

17.

Lau K, Baylink D, Strong D . 1,25-Dihydroxyvitamin D3 stimulates both alkaline phosphatase gene transcription and mRNA stability in human bone cells. Arch Biochem Biophys. 1991; 291(2):316-25. DOI: 10.1016/0003-9861(91)90141-5. View

18.

Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa S, Sugawara H . Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract. 2011; 92(2):181-6. DOI: 10.1016/j.diabres.2011.01.009. View

19.

Uehara M . Isoflavone metabolism and bone-sparing effects of daidzein-metabolites. J Clin Biochem Nutr. 2013; 52(3):193-201. PMC: 3652301. DOI: 10.3164/jcbn.13-2. View

20.

Wei S, Chen Y, Xu X . Progress on the pharmacological research of puerarin: a review. Chin J Nat Med. 2014; 12(6):407-14. DOI: 10.1016/S1875-5364(14)60064-9. View